RCS - ValiRx PLC - Live Shareholder Q&A and Investor presentations

ValiRxAnnouncement

11/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211111:nRSK0185Sa&default-theme=true

RNS Number : 0185S  ValiRx PLC  11 November 2021

11 November 2021

 

ValiRx PLC ("ValiRx" or the "Company")

 

Live Shareholder Q&A and Investor presentations

 

Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health, invites
shareholders to join the CEO, Chairman and Corporate Development Manager in a
Zoom webinar on 25 November 2021 at 2pm (UK). Registration prior to the event
is recommended to ensure all notifications about the webinar are received by
participants. Registration details will be available on the ValiRx website
closer to the event. The format will comprise a short presentation by the
Company on latest developments, followed by an invitation to shareholders to
activate their cameras and speak directly with the ValiRx team. A recording of
the event will be available to view from the ValiRx website shortly after the
event concludes.

LSE Investor Presentation: CEO, Dr Suzy Dilly will also be presenting at this
event on the evening of 7 December (6pm - 8pm (UK)). Prior registration is
required directly with LSE, which can be accessed at
https://us02web.zoom.us/webinar/register/1116364722800/WN_oBS-LVJrQJ-K9iQlDe3nMA
(https://eu-west-1.protection.sophos.com?d=zoom.us&u=aHR0cHM6Ly91czAyd2ViLnpvb20udXMvd2ViaW5hci9yZWdpc3Rlci8xMTE2MzY0NzIyODAwL1dOX29CUy1MVkpyUUotSzlpUWxEZTNuTUE=&i=NTdmYjZhY2YwMGFiZGYxNGYzOTNjYzlm&t=MmNTSlluZndSOHgzeXB5TmlSL2N1NUErRkxjYWZrcmlHRFp5NDkxZ3Z0MD0=&h=9479920e93be4717af0714dcab53d7bd)
.  The format will be a short presentation and audience Q&A.

Corporate Update: The Company is also pleased to inform shareholders that the
entry on www.clinicaltrials.gov (http://www.clinicaltrials.gov) for the
recently completed VAL201 clinical trial has now been finalised with the
addition of a summary of raw data results.

Dr Suzy Dilly, CEO of ValiRx commented: "I am looking forward to joining our
shareholders in further live discussions as we continue building our events
schedule to achieve transparent shareholder communications. Further
conversations about our recent scientific and commercial advances, as well as
conversations around our emerging strategy in Women's Health are important as
we wish to ensure that shareholders understand how we are intending to
continue to build long term value into the Company."

 

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com

 Cenkos Securities Limited (Broker)                  Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework towards enabling rapid translation of innovative science
into clinical development.

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the aim of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

The Company listed on the AIM Market of the London Stock Exchange in October
2006 and trades under the ticker symbol: VAL.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZMMMGGDGMZZ